Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00455975
Status:
COMPLETED
Last Update Posted:
2014-12-22
First Post:
2007-04-03
Brief Title:
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma
Detailed Description:
Bevacizumab is considered a targeted drug Targeted drugs act on specific receptors on a cell Bevacizumab blocks receptors that help cancer cells develop blood supplies so that the cancer can grow These specific receptors are found in greater numbers in kidney cancer In that regard bevacizumab will be tested in 2 doses that are higher than non-kidney cancer treatments with bevacizumab
One group of patients will receive bevacizumab at 15 mg per kg by vein every 2 weeks A total of 75 patients will be treated with this dose
If this dose is well tolerated a second group of patients will receive bevacizumab at 15mg per kg by vein weekly
One group of patients will receive bevacizumab at 15 mg per kg by vein every 2 weeks A total of 75 patients will be treated with this dose
If this dose is well tolerated a second group of patients will receive bevacizumab at 15mg per kg by vein weekly
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AVF 3913s | None | None | None |